ArticleMedical oncology (Northwood, London, England)2026
Novel patient-derived tongue squamous cell carcinoma cell lines from non-smokers: 3D and in vivo models for drug response studies.
Article in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tongue squamous cell carcinoma (TSCC) is the most prevalent and aggressive subtype of oral squamous cell carcinoma (OSCC), with a high incidence of lymph node metastasis even in early stages. The five-year overall survival rates remain low, around 50% in advanced stages. Cell line models are essential tools to understand the complexity of TSCC and develop new therapies. However, most commercially available TSCC cell lines are derived from patients with a history of tobacco use or have unknown exposure backgrounds. We established two novel TSCC cell lines, LMSCC03 and LMSCC16, derived from non-smoking and treatment naïve Brazilian patients. These cell lines were characterized by doubling time, 3D culture (spheroids and organoids), tumorigenicity through xenotransplantation in nude mice, immunohistochemical expression of key OSCC biomarkers and drug response. Genetic identity was confirmed by STR profiling. LMSCC03 and LMSCC16 displayed epithelial morphology and pan-cytokeratin staining. They demonstrated in vitro capacity to form spheroids and organoids, and generated tumors in vivo. STR profiling confirmed their novelty relative to existing cell lines in the DSMZ database. Protein analysis revealed high p53 nuclear levels in LMSCC16 cells. Interestingly, CD44 and c-Myc expression were observed only in fibroblast-enriched cultures, but not in the epithelial LMSCC03 and LMSCC16 cells. LMSCC16 also harbored two TP53 mutations and showed increased resistance to Cisplatin and Paclitaxel compared to established TSCC cell lines. Cisplatin treatment in spheroids reduced OCT4, CCND1, CCNB1, and CDH1 gene expression in LMSCC03. In contrast, LMSCC16 showed significant modulation of OCT4, increased CCND1 and CCNB1 expression, and reduced CDH1 levels following treatment. We established two novel TSCC cell lines that represent clinically relevant models to explore TSCC carcinogenesis and therapeutic responses, particularly in non-smoking populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.